Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine,(CAIV-T)
NCT00192231
ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
- Healthy adults aged 18 to 59 years or > 60 years.
- Female subjects of childbearing potential who had a negative urine pregnancy test result prior to study vaccination. Females who were surgically sterilized or post-menopausal did not require pregnancy testing.
- Adults who were determined by medical history, physical examination and clinical judgment eligible for this study. Subjects with stable pre-existing disease, defined as disease not requiring change in therapy or hospitalization within 12 weeks before receipt of study vaccination, were eligible.
- Subjects who provided written informed consent after the nature of the study was explained.
- Subjects who were available for the duration of the study (from enrollment to study completion).
- Subjects who could be reached by study staff for the post-vaccination contact [via telephone, clinic or home visit].
- Subjects who resided in a nursing home or long-term care facility or other institution
receiving skilled or semi-skilled nursing care. An ambulatory subject who resided in a
retirement home or village was eligible for participation.
- Subjects with evidence of dementia or other severe cognitive impairment based on Mini
Mental State Examination (MMSE) score of 22 or greater. Note: Administration of MMSE
was performed only if clinically indicated.
For all study subjects:
- Subjects who were perceived to be unavailable or difficult to contact for evaluation
of study visits during the study period.
- Subjects with a known or suspected disease of the immune system or those receiving
immunosuppressive therapy, including systemic corticosteroids; or cytotoxic agents.
- Subjects who received any blood products, including immunoglobulin, in the period from
six months prior to vaccination through to the conclusion of the study.
- Subjects who resided in the same household as an immunosuppressed or immunocompromised
individual.
- Subjects with a documented history of hypersensitivity to egg or egg protein or any
other component of the study vaccine or placebo.
- Subjects who were administered any live virus vaccine within one month prior to
enrollment.
- Subjects for whom there was intent to administer any other investigational vaccine or
agent from one month prior to enrollment through the conclusion of the study.
- Subjects who received a dose of influenza treatment (commercial or investigational)
one month prior to enrollment. Prophylactic use of influenza antivirals was not
permitted.
- Subjects who received any influenza vaccine in the six months prior to enrollment, or
nonstudy influenza vaccine since enrollment.
- Subjects with any medical conditions that in the opinion of the investigator might
interfere with the interpretation of the study results.
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- New Port Richey, Florida
- Pittsburgh, Pennsylvania
- Durban North, Dwazulu Natal
- Hazelwood, Pretoria
- Amanzimtoti,
- Scottburgh South,
- Heidelburg, Victoria
Descriptive Information | ||||
---|---|---|---|---|
Brief Title ICMJE | Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine,(CAIV-T) | |||
Official Title ICMJE | A Randomized, Double-Blind, Placebo-Controlled Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine, Trivalent Types A & B, Live Cold Adapted (CAIV-T) in Healthy Adults Aged 18 and Older | |||
Brief Summary | The primary objective of this study was to perform a variety of immunological assays on blood, serum, nasal wash samples, and cells obtained from healthy adult subjects for the purpose of developing assays for application in the further investigation of immune responses generated by influenza virus vaccine, trivalent, types A and B, live, cold-adapted (liquid CAIV-T). | |||
Detailed Description | Not Provided | |||
Study Type ICMJE | Interventional | |||
Study Phase ICMJE | Phase 3 | |||
Study Design ICMJE | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double Primary Purpose: Prevention | |||
Condition ICMJE | Influenza | |||
Intervention ICMJE | Biological: CAIV-T | |||
Study Arms ICMJE | Not Provided | |||
Publications * | Not Provided | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
Recruitment Information | ||||
Recruitment Status ICMJE | Completed | |||
Enrollment ICMJE | 120 | |||
Original Enrollment ICMJE | Same as current | |||
Study Completion Date ICMJE | June 2001 | |||
Primary Completion Date | Not Provided | |||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
For all study subjects:
| |||
Sex/Gender ICMJE |
| |||
Ages ICMJE | 18 Years and older (Adult, Older Adult) | |||
Accepts Healthy Volunteers ICMJE | Yes | |||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||
Listed Location Countries ICMJE | Australia | |||
Removed Location Countries | ||||
Administrative Information | ||||
NCT Number ICMJE | NCT00192231 | |||
Other Study ID Numbers ICMJE | D153 P510 | |||
Has Data Monitoring Committee | Not Provided | |||
U.S. FDA-regulated Product | Not Provided | |||
IPD Sharing Statement ICMJE | Not Provided | |||
Responsible Party | Not Provided | |||
Study Sponsor ICMJE | MedImmune LLC | |||
Collaborators ICMJE | Wyeth is now a wholly owned subsidiary of Pfizer | |||
Investigators ICMJE |
| |||
PRS Account | MedImmune LLC | |||
Verification Date | October 2006 | |||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |